Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
This research study is for people with advanced neuroendocrine tumours of the gut or pancreas (GEP-NETs) that have spread or can't be removed, and that are found to have a specific marker (Somatostatin Receptor Positive). The study is testing a new treatment called [177Lu]Lu-DOTA-TATE, given alongside a standard medicine called Octreotide LAR. This combination will be compared to receiving Octreotide LAR on its own. Researchers want to see if the new combination is better at controlling the cancer and if it's safe for patients. Participants must be at least 12 years old and have been recently diagnosed with this type of cancer, with what doctors call a 'high disease burden'.
En un coup d'œil
De quoi parle cette étude ?
This study is designed to help us learn more about a type of cancer called Gastroenteropancreatic Neuroendocrine Tumours, or GEP-NETs for short. These are uncommon cancers that can grow in the gut or pancreas. When these cancers are advanced, it means they might have spread to other parts of the body or are in a place that makes them hard to remove with surgery. The main goal of this study is to test a new treatment to see if it can help patients with this advanced condition.
The new treatment involves a medicine called [177Lu]Lu-DOTA-TATE, which is given together with an existing medicine called Octreotide LAR. Octreotide LAR is already used to treat GEP-NETs. The study will compare patients who receive both the new medicine and Octreotide LAR, to patients who just receive Octreotide LAR. We want to find out if combining these treatments is more effective at controlling the cancer and whether it's safe for people to take.
Taking part in a study like this helps doctors understand new ways to treat diseases. By comparing the usual treatment with a new one, researchers can see if the new approach is better for patients now and in the future. This kind of research is very important for improving care for people living with GEP-NETs.
Points clés
- This study is for advanced gut or pancreatic neuroendocrine tumours (GEP-NETs).
- It tests a new medicine combination against a standard treatment.
- Participants must be at least 12 years old.
- The study aims to see if the new treatment is safe and more effective.
- Your health will be closely watched throughout the study.
- Vous pouvez vous retirer de l'étude à tout moment.
Qui peut être éligible ?
This study is looking for people who have been diagnosed with a specific type of advanced neuroendocrine tumour affecting the gut or pancreas (GEP-NETs). The cancer needs to be well-understood by doctors, with a recent diagnosis (within the last six months) and it shouldn't be possible to cure with surgery. Participants must also have specific markers on their cancer, which doctors can check with special scans.
To join, you need to be at least 12 years old. Doctors will consider if your cancer has a 'high disease burden'. This could mean the main tumour or a tumour that has spread is bigger than 4cm, or there are several tumours larger than 2cm. Other signs of high disease burden include changes in certain blood tests, cancer in your bones or the lining of your belly, or if the cancer is causing bothersome symptoms like pain, tiredness, or weight loss.
Before you start, doctors will also check your general health, including your blood counts and how well your kidneys and liver are working. These checks are important to make sure it's safe for you to take part in the study medicines.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Have I been diagnosed with an advanced GEP-NET within the last 6 months?
- Do doctors think my cancer has a 'high disease burden' (e.g., larger tumours, affecting bones)?
- Ai-je 12 ans ou plus ?
- Have scans shown my tumour has specific 'somatostatin receptors'?
- Are my blood tests, kidney, and liver functions generally healthy enough for the study?
En quoi consiste la participation ?
If you decide to take part, the study will involve several stages. First, there's a 'screening phase' where doctors will do various tests and scans to make sure you meet all the requirements for the study. This might include blood tests and special scans to look at your tumour.
If you're eligible, you'll then enter the 'treatment phase'. During this time, you'll receive either the new combination treatment or Octreotide LAR on its own. You'll have regular visits to the clinic for your treatments, check-ups, blood tests, and scans. The medical team will keep a close eye on you to see how you're responding to the treatment and to check for any side effects.
After your treatment is complete, there will be a 'follow-up phase'. This means you'll continue to have check-ups for a period of time to monitor your health and long-term effects of the treatment. The total length of time you'll be involved in the study, from your first screening appointment to your last follow-up, will depend on the study plan, but it generally lasts for a number of years.
Risques et avantages potentiels
Locations (67)
- Mayo Clinic ArizonaCode postal vérifiéScottsdale, États-Unis· Recrutement
- Highlands Oncology GroupCode postal vérifiéFayetteville, United States· Recrutement
- Rocky Mountain Cancer CentersCode postal vérifiéDenver, United States· Recrutement
- Hôpital de HartfordCode postal vérifiéHartford, États-Unis· Recrutement
- Yale New Haven HospitalCode postal vérifiéNew Haven, États-Unis· Recrutement
- Mayo Clinic JacksonvilleCode postal vérifiéJacksonville, États-Unis· Recrutement
- AdventHealthCode postal vérifiéOrlando, United States· Recrutement
- Piedmont HealthcareCode postal vérifiéAtlanta, États-Unis· Recrutement
- Winship Cancer InstituteCode postal vérifiéAtlanta, États-Unis· Recrutement
- St Elizabeth HealthcareCode postal vérifiéEdgewood, United States· Recrutement
- LSU Medical CenterCode postal vérifiéNouvelle-Orléans, États-Unis· Recrutement
- Henry Ford HospitalCode postal vérifiéDetroit, United States· Recrutement
Questions fréquentes
What are GEP-NETs?
GEP-NETs are rare types of cancer that start in special cells in your gut or pancreas.
What does 'advanced' cancer mean in this study?
It means the cancer has spread from where it started or can't be fully removed by surgery.
What is Octreotide LAR?
Octreotide LAR is a medicine already used to treat GEP-NETs to help control tumour growth and symptoms.
Will I definitely get the new medicine?
Not necessarily. This study compares two groups, so you might get the new medicine alongside the standard treatment, or just the standard treatment.
Puis-je quitter l'étude si je change d'avis ?
Yes, you can choose to leave the study at any time, and this won't affect your medical care.
Comment en savoir plus
Novartis Pharmaceutiques
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.